MedTrace Logo

Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome

NCT00659321 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2012-01-11

No results posted yet for this study

Summary

Placebo controlled evaluation of effectiveness of nicotine acid in treatment of postprandial dyslipidemia in patients with metabolic syndrome. Nicotine acid decreases postprandial hyperlipidaemia in patients with metabolic syndrome which reduces the low-grade inflammation and the risk of atherosclerosis.

Conditions

  • Metabolic Syndrome
  • Dyslipidaemia

Interventions

DRUG

nicotine acid

16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication

DRUG

placebo

16 weeks treatment with placebo

Sponsors & Collaborators

  • Technische Universität Dresden

    collaborator OTHER

  • University of Regensburg

    collaborator OTHER

  • GWT-TUD GmbH

    lead OTHER

Principal Investigators

  • Markolf Hanefeld, MD, PhD · GWT-TUD GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-09-30
Completion
2008-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00659321 on ClinicalTrials.gov